University of Debrecen Clinical Center
Welcome,         Profile    Billing    Logout  
 1 Trial 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Poka, Robert
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
ENGOT en-21, NCT05797831: Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Recruiting
2/3
268
Europe, Canada, US, RoW
Navtemadlin, KRT-232, Navtemadlin Placebo
Kartos Therapeutics, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Endometrial Cancer
08/25
07/27
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
Nagy, Andrea
NCT03978000 / 2018-000754-22: IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

Active, not recruiting
3
2158
Europe, US, RoW
IBP-9414, Placebo
Infant Bacterial Therapeutics
Necrotizing Enterocolitis
06/24
07/24
TRECOS, NCT06264674: Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma ().

Active, not recruiting
3
837
Europe, RoW
CHF5993 200/6/12.5 μg pMDI HFA-152a, HFA-152a propellant, Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a, HFA-134a propellant
Chiesi Farmaceutici S.p.A.
Asthma
07/25
09/25

Download Options